Scholarlink

Introduction <p>Automated insulin delivery (AID) systems have demonstrated safety and efficacy in improving glycemic control during pregnancy in women with type 1 diabetes (T1D). However, evidence regarding their use during labour and delivery is extremely limited, and no randomized controlled trials have specifically evaluated intrapartum maternal and neonatal outcomes.</p> Case Presentation <p>We report a retrospective case series of four women with T1D who used AID systems (Tandem Control-IQ<sup>®</sup> or MiniMed 780G<sup>®</sup>) before and throughout pregnancy and labour. Glycemic control during the 24&#xa0;h of delivery was assessed using time in range (TIR, 70–180&#xa0;mg/dL) and pregnancy-specific time in range (TIRp, 63–140&#xa0;mg/dL). During labour, TIR ranged from 81% to 97%, and TIRp ranged from 65% to 91%. Three of four patients achieved TIRp &gt; 70%, as recommended by international consensus guidelines. No episodes of maternal hypoglycemia or diabetic ketoacidosis occurred. Postpartum insulin requirements decreased by 12–58% compared with the week before delivery. Two newborns experienced hypoglycemia within the first 24&#xa0;h, managed with milk feeding or intravenous glucose; one required neonatal intensive care unit admission for respiratory distress syndrome. No other major perinatal complications were observed.</p> Conclusion <p>In this small real-world case series, the use of different AID systems during labour was associated with excellent intrapartum glycemic control and no acute maternal complications. Neonatal outcomes were consistent with those reported in literature for pregnancies complicated by T1D. These findings support the feasibility and safety of continuing AID therapy during labour, although larger prospective studies are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intrapartum Use of AID Systems in Women with Type 1 Diabetes: A Case Series

  • 期刊论文

  • 发表日期：

    2026年7月14日

查看全文
  • Carla Cervello,
  • Giordano Spacco,
  • Lucia Briatore,
  • Nicola Minuto,
  • Marta Bassi

摘要

Introduction

Automated insulin delivery (AID) systems have demonstrated safety and efficacy in improving glycemic control during pregnancy in women with type 1 diabetes (T1D). However, evidence regarding their use during labour and delivery is extremely limited, and no randomized controlled trials have specifically evaluated intrapartum maternal and neonatal outcomes.

Case Presentation

We report a retrospective case series of four women with T1D who used AID systems (Tandem Control-IQ® or MiniMed 780G®) before and throughout pregnancy and labour. Glycemic control during the 24 h of delivery was assessed using time in range (TIR, 70–180 mg/dL) and pregnancy-specific time in range (TIRp, 63–140 mg/dL). During labour, TIR ranged from 81% to 97%, and TIRp ranged from 65% to 91%. Three of four patients achieved TIRp > 70%, as recommended by international consensus guidelines. No episodes of maternal hypoglycemia or diabetic ketoacidosis occurred. Postpartum insulin requirements decreased by 12–58% compared with the week before delivery. Two newborns experienced hypoglycemia within the first 24 h, managed with milk feeding or intravenous glucose; one required neonatal intensive care unit admission for respiratory distress syndrome. No other major perinatal complications were observed.

Conclusion

In this small real-world case series, the use of different AID systems during labour was associated with excellent intrapartum glycemic control and no acute maternal complications. Neonatal outcomes were consistent with those reported in literature for pregnancies complicated by T1D. These findings support the feasibility and safety of continuing AID therapy during labour, although larger prospective studies are needed.